Key result
AKI biomarker panels may help elucidate cardiorenal cross-talk and guide therapy.
Biomarker panels may soon provide valuable information to guide therapy in patients with cardiorenal syndrome.
Biomarker panels should not yet guide cardiorenal therapy; leaves open prospective validation of AKI markers for organ cross-talk.
Cardiac and renal diseases often coexist. Treatment may prove difficult as early diagnosis and effective therapy may be hindered by a lack of robust markers of disease activity. However, several candidate molecules are now available which may help elucidate the complexities of organ cross-talk, enabling effective therapies. We discuss the available data on the commonly studied biomarkers of acute kidney injury with reference to the cardiorenal syndrome. Furthermore, we propose how the use of biomarkers as a panel may provide information which can guide therapy. Although this is a relatively new field, advances are rapid, and such options may well be available to the clinician soon.
No takes yet. Share an insight, caveat, or question.
Forni et al. (2014) conducted a review in Cardiorenal Syndrome. Biomarkers of acute kidney injury was evaluated. Biomarkers of acute kidney injury may help elucidate organ cross-talk in cardiorenal syndrome and guide therapy when used as a panel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: